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Abstract
Background: About one third of patients with epilepsy become refractory to therapy despite receiving adequate medical
treatment, possibly from multidrug resistance. P-glycoprotein, encoded by multidrug resistance protein-1 (MDR1) gene, at
the blood brain barrier is considered as a major factor mediating drug efflux and contributing to resistance. Given that
peripheral blood mononuclear cells (PBMNCs) express MDR1, we investigated a MDR1 status of PBMNCs in various subsets
of epilepsy patients and demonstrated their association with clinical characteristics.
Methodology/Principal Findings: Clinical and MDR1 data were collected from 140 patients with epilepsy, 30 healthy
volunteers, and 20 control patients taking anti-epileptic drugs. PBMNCs were isolated, and basal MDR1 levels and MDR1
conformational change levels were measured by flow cytometry. MDR1 profiles were analyzed according to various clinical
parameters, including seizure frequency and number of medications used in epilepsy patients. Epilepsy patients had a
higher basal MDR1 level than non-epilepsy groups (p,0.01). Among epilepsy patients, there is a tendency for higher seizure
frequency group to have higher basal MDR1 level (p=0.059). The MDR1 conformational change level was significantly
higher in the high-medication-use group than the low-use group (p=0.028). Basal MDR1 (OR=1.16 [95% CI: 1.060–1.268])
and conformational change level (OR=1.11 [95% CI: 1.02–1.20]) were independent predictors for seizure frequency and
number of medications, respectively.
Conclusions/Significance: The MDR1 profile of PBMNCs is associated with seizure frequency and medication conditions in
patients with epilepsy.
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Introduction
Almost one-third of patients with epilepsy cannot achieve
seizure freedom and have a poor prognosis despite receiving
adequate medical treatment and the administration of multiple
anti-epileptic drugs (AEDs) [1]. Although the mechanism of this
refractoriness remains unclear, the prediction of medically
refractory epilepsy is an important concern of current epilepsy
research.
Multidrug resistance protein-1 (MDR1), multidrug resistance-
related proteins and breast cancer resistance proteins comprise
members of the multidrug resistance protein family. MDR1, first
known as a drug-resistance protein in tumor cells [2], is a 170- to
180-kDa membrane protein. MDR1 mediates ATP-dependent
drug efflux for various xenobiotics and drugs [3,4]._ENREF_2
The apical membranes of capillary endothelial cells of the blood-
brain barrier express MDR1, which contributes to drug efflux
from the brain to the systemic circulation. Despite the protective
role of transporter proteins, AED penetration to the brain is
compromised by MDR1 [5–7]. For intractable patients with
epilepsy, drug resistance is likely caused by a high level of MDR1
in the brain endothelium [8–10].
Recent studies suggest that molecular profile of peripheral blood
mononuclear cells (PBMNCs) could be used as biopsy material to
reflect physiological condition of the body and a possible marker
for predicting the treatment outcome of various diseases [11–17].
Given that human peripheral blood cells also express MDR1
proteins and play a role in brain endothelial cell turnover [18], we
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36985hypothesized that the MDR1 profile of these cells might be related
to drug resistance of epilepsy.
In this study, we examined epilepsy patients, healthy volunteers,
and non-epilepsy patients taking AEDs. We also divided refractory
epilepsy patients according to their seizure frequency and the
number of medications required to control their seizures, which
could be regarded as criteria of refractoriness of epilepsy [1,19].
For MDR1 status, we examined basal MDR1 level and
conformational change level of PBMNCs by flow cytometry. Both
the basal MDR1 level and conformational change level were
measured using the UIC2 antibody, which binds to the MDR1
protein and has high affinity to the activated ATP-hydrolyzing
form of MDR1 in the presence of substrate [20,21]. The enhanced
affinity of this antibody allows for detection of cells with relatively
low MDR1 expression. The basal MDR1 level, which was
analyzed by a conventional flow cytometry after staining
unstimulated PBMNCs, reflects the number of cells expressing
high level of MDR1 protein. The MDR1 conformational change
level measured in vinblastine-treated PBMNCs, which have
activated MDR1, reflects the number of all cells with functional
MDR1 which has the ability of actual pumping action in
peripheral blood [22,23]. Several clinical parameters were assessed
in association with the categorized MDR1 data.
Materials and Methods
Ethics Statement
The study protocol was approved by the Scientific Review
Committee and the Institutional Review Board of Seoul National
University Hospital, and all enrolled subjects provided written
informed consent as required by the Declaration of Helsinki.
Study Population
We studied 117 refractory and 23 seizure-free epilepsy patients
who were diagnosed with temporal lobe epilepsy, and 20 control
patients taking AEDs. The seizure-free epilepsy patients didn’t
experience seizure for at least one year. The control with AEDs
consisted of non-epilepsy patients taking AEDs because of
neuropathic pain, headache and etc. The patients underwent
medical follow-up at the Department of Neurology, Seoul
National University Hospital, from February 2008 to December
2010. Thirty healthy volunteers were recruited for the control
group. A questionnaire was developed by the authors to evaluate
the patients’ demographic data and medical histories.
PBMNC Preparation and Flow-cytometric Analysis
Materials for the flow cytometry staining including MDR1
antibody (UIC2 antibody), dimethyl sulfoxide (DMSO), vinblas-
tine, working solutions, and binding buffers were all included in
the MDR1 shift assay kit (Chemicon International, Temecula, CA,
USA). Peripheral blood samples (5cc) were obtained from all
enrolled subjects. The heparinized blood samples were added to
Histopaque (Sigma-Aldrich, St. Louis, MO, USA) and centrifuged
at 4006g for 30 min to separate the PBMNCs. Isolated cells were
counted and centrifuged at 200 6g for 5 min. The supernatant
was removed, and the pellets were resuspended to 1610
6 cells/mL
in warmed UIC2 binding buffer (1% bovine serum albumin in
PBS). Basal MDR1 level assay procedure is as follows: cells were
divided into two groups and treated with 5 mL of DMSO
respectively. The tubes were incubated at 37uC for 10 min;
25 mL of the kit’s IgG2a antibody working solution was added to
one group and 25 mL of UIC2 antibody working solution was
added to the other group. The tubes were incubated at 37uC for
another 15 min and washed three times with cold UIC2 binding
buffer at 2006g for 10 min at 4uC. The cells were resuspended in
250 mL ice-cold secondary antibody working solution and
incubated for 15 min at 4uC in the dark. After being washed
three times, the cells were resuspended in 0.5 mL ice-cold
propidium iodide staining buffer. Samples were then maintained
on ice until analysis with a flow cytometer (FACSCalibur, BD
Biosciences, San Jose, CA, USA), using FL2 channel for indirect
UIC2 staining and FL3 channel for propidium iodide to exclude
dead cells. To filter out cell debris, forward scatter and side scatter
of the cells were measured and lymphocytes and monocytes
regions were gated (Fig. 1A). After gating cell populations,
propidium iodide negative cells were gated to wipe out dead cells
(Fig. 1B). Using this cell population, baseline for gating positive
population was confirmed using IgG2a isotype. UIC2 positive
populations were gated using this baseline and positive cell
number was counted using FL2 channel (Fig. 1C). Positive level
was calculated as a percentage of UIC2 positive cell number in
whole live cell population. For MDR1 conformational change
level assay, we used 5 mL of 22 mM vinblastine instead of DMSO
and rest of the process is identical to basal MDR1 level. UIC2
antibody reacts with membrane bound MDR1 and their reactivity
Figure 1. Analysis of MDR1 profiles of PBMNCs with the flow
cytometry. (A) PBMNCs were stained with MDR1 antibody and
propidium iodide (PI) and examined forward scatter (FSC) and side
scatter (SSC) and leukocytes were gated (R1) to exclude aggregates and
debris. (B) In R1 gated population, PI positive dead cells were excluded
and PI negative live cells were gated (lined box). (C) In gated cells, the
MDR1-positive population was assessed using the baseline determined
from a negative control of IgG2a background staining (dotted box). (D)
Representative histogram figures show the basal MDR1 level (left) and
conformational change level (right).
doi:10.1371/journal.pone.0036985.g001
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basal MDR1 level reflects the number of cells expressing high level
of MDR1 and the conformational change level reflects all
functional MDR1 level in PBMNCs [22,23].
Statistical Analysis
Data were analyzed using SPSS version 17.0 (SPSS Inc.,
Chicago, IL, USA). Student’s t-test or analysis of variance with
subsequent Tukey’s b-test for MDR1 conformational change level,
Mann-whitheny U test or Kruskal-Wallis test for basal MDR1
level were used to compare mean values for continuous variables,
and the chi-squared test was used for categorical variables. We
classified refractory epilepsy patients in terms of seizure frequency.
The low-frequency group had fewer than one seizure per week
(n=69, 59%) and the high-frequency group had one or more
seizures per week (n=48, 41%). We also classified the patients into
those taking three or more medications (n=63, 54%) and those
taking fewer than three (n=54, 46%). To identify factors helping
to predict high seizure frequency and medication number,
multiple logistic regression analysis was performed with significant
variables defined from the initial univariate analysis, and statistical
significance was set at p,0.05.
Results
Patient Characteristics
The study was carried out in 190 subjects, including 117
refractory epilepsy patients, 23 seizure-free epilepsy patients, 30
healthy volunteers, and 20 control patients taking AEDs. The
baseline characteristics of the refractory epilepsy patients are
summarized in Table 1. Characteristics, including age, number of
AEDs and type of AEDs, of control groups are represented in
Table 2.
MDR1 Profiles Among Patients
The basal MDR1 and conformational change level of MDR1 in
the PBMNCs were analyzed using flow cytometry. Representative
superimposed histograms of basal MDR1 level and conformation-
al change level are presented (Fig. 1D). Kruskal-Wallis test
confirmed significant differences in the basal MDR1 levels among
groups (p,0.01). Patients with epilepsy had higher basal MDR1
levels than the healthy volunteers and control patients taking
AEDs (p,0.01; Fig. 2A). The conformational change level was not
significantly different among groups (Fig. 2B).
MDR1 Profiles According to Seizure Frequency
We classified refractory patients into high- and low-seizure-
frequency groups (Table 3). The high-frequency group took more
medications (3.261.4 vs. 2.661.7, p=0.015) than the low-
frequency group. The high-frequency group tended to have a
higher basal MDR1 level (9.766.2% vs. 7.264.0%, p=0.059)
(Fig. 2C). Moreover, independent associations with seizure
frequency were noted for basal MDR1 level (p=0.001), number
of medications (p=0.022), and a history of temporal lobectomy
(p=0.004). The odds ratio of the basal MDR1 level for seizure
frequency was 1.160 (95% CI, 1.060–1.268) after adjustment
(Table 4).
MDR1 Profiles According to AED Intake
To evaluate the association between the MDR1 profile and
drug resistance, we categorized patients into high- and low-
Table 1. Refractory epilepsy patient demographics.
Parameters Refractory epilepsy (n =117)
Age (year) 37.8610.8
Age of onset (year) 20.3613.4
BMI 35.268.1
Hypertension (n, %) 10 (8.5)
Diabetes (n, %) 3 (2.6)
Hyperlipidemia (n, %) 1 (1)
Duration of epilepsy (year) 18.869.2
Frequencies of seizures (per week) 1.764.5
Seizure duration (sec) 1106162.9
Temporal lobectomy (n, %) 10 (8.5)
Smoking (n, %) 14 (12)
Febrile seizure (n, %) 19 (16.2)
GTCS : CPS : SPS (%) 57.1: 25 : 17.9
Family history (n, %) 8 (6.8)
Number of AEDs 2.861.3
GTCS=generalized tonic-clonic seizure; CPS=complex partial seizure;
SPS=simple partial seizure.
doi:10.1371/journal.pone.0036985.t001
Table 2. Control groups characteristics.
Parameters Healthy control Non-epilepsy with AEDs Seizure-free epilepsy
(n=30) (n=20) (n=23)
Age (year) 37.8610.8 49.9613.6 32.3610.7
Number of AEDs 0 1.160.3 1.360.4
Type of AEDs (n) – VPA(15), PRE(2), VPA(3), CBZ(2), OCZ(5),
TPM(1), VPA+PRE(2) LEV(1), TPM(2), LTG(2),
CBZ+LTG(1), CBZ+LEV(1),
LEV+LTG(1), CBZ+CLO(1),
TPM+CLO(1), DPH+PB(1),
LEV+TPM(1), CBZ+TPM(1)
VPA=valproate; CBZ=carbamazepine; OCZ=oxcarbazepine; LEV=levetiracetam; TPM=topiramate; LTG=lamotrigine; CLO=clobazam; PB=phenobarbital;
PRE=pregabalin.
doi:10.1371/journal.pone.0036985.t002
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in Table 5. The high-medication group had a younger age of onset
and a longer duration of epilepsy (17.6613.2 vs. 23.3613.1 years,
p=0.02; 20.6610.8 vs. 13.5610 years, p,0.05) (Fig. 2D). The
mean seizure frequency tended to be higher in the high-
medication group, but it was not significant. In terms of MDR1
status, we found a higher conformational change level in the high-
medication group than in the low-medication group (p=0.028),
whereas basal MDR1 level was not significantly different between
these groups. Multiple logistic regression analysis indicated that
the duration of epilepsy and the conformational change level were
significant independent predictors of the number of AEDs taken
(Table 4). The odds ratio of conformational change level of MDR1
for medication number was 1.11 (95% CI, 1.02–1.20).
Discussion
We assayed the MDR1 profile of PBMNCs in epilepsy patients
by flow cytometry. We categorized 117 patients with refractory
epilepsy according to seizure frequency and the number of
medications taken. These two parameters could be regarded as
criteria for the severity of refractoriness [19,24]. Basal MDR1 level
and conformational change level were higher in the high-seizure
frequency group and high-medication group, respectively. Multi-
ple logistic regression analysis revealed these as independently
related factors.
Our results suggested that the basal MDR1 level was higher in
epilepsy patients compared with healthy volunteers and non-
epilepsy patients taking AEDs. The AEDs were administered to
non-epilepsy patients for treatment of migraine, neuropathic pain,
and etc. The regimens included valproic acid, topiramate or
pregabalin, and their dosage ranges were much lower than those
Figure 2. MDR1 profiles among groups and refractory epilepsy patients. Graphs represent (A) basal MDR1 level and (B) conformational
change level among the groups. Graphs represent (C) basal MDR1 level between low- and high-seizure-frequency groups and (D) conformational
change level between low- and high-medication-use groups in the refractory epilepsy patients. The horizontal lines represent the median level and
standard error of the mean.
doi:10.1371/journal.pone.0036985.g002
Table 3. Correlation between seizure frequency and clinical
parameters.
Seizure frequency
Parameters Low (n=69) High (n=48) p Value
Frequency of seizure
(per week)
0.160.2 466.5 ,0.001
Age (year) 38611 37.5610.7 0.817
Age of onset (year) 20.8613.2 19.5613.7 0.632
Duration of epilepsy (year) 17611.8 17.7610 0.752
Number of AEDs 2.661.2 3.261.4 0.015*
Seizure duration (sec) 118.86172.0 98.66150.4 0.515
BMI 35.867.6 34.368.9 0.323
Hypertension: n (%) 5 (7.2) 5 (10.4) 0.738
Diabetes: n (%) 0 (0) 3 (6.3) 0.066
Hyperlipidemia: n (%) 0 (0) 1 (2.1) 0.410
Smoking: n (%) 7 (10.1) 7 (14.6) 0.467
Temporal lobectomy: n (%) 3 (4.3) 7 (14.6) 0.089
Febrile seizure: n (%) 16 (23.2) 3 (6.3) 0.015*
Family history: n (%) 4 (5.8) 4 (8.3) 0.715
Semiology: (GTCS:
CPS: SPS,%)
58.2: 23.9: 17.9 55.6: 26.7: 17.8 0.943
Basal MDR1 level (%) 7.264.0 9.766.2 0.009**
Conformational
change level (%)
14.265.2 14.966.0 0.512
BMI=body mass index.
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0036985.t003
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different type of anticonvulsants could influence lower MDR1
level of PBMNCs in non-epilepsy with AEDs than epilepsy with
AEDs. However, we found no significant difference according to
the types of AEDs among epilepsy patients. In this study, the high-
seizure-frequency group also took more medications. This group
experienced recurrent seizures despite adequate administration of
multiple AEDs. Although these drugs control seizures initially,
drug resistance may gradually emerge from the overexpression of
MDR1, leading to refractory epilepsy [25]. Our result shows that
the patients who experience more seizure tend to have more cells
expressing high level of MDR1 in peripheral blood. In addition to
categorizing patients according to seizure frequency, we examined
high- and low-medication groups. The use of more medications
indicates an insufficient treatment outcome from a single major
AED. This result suggests that the high-medication patients have
more cells having functional MDR1 in PBMNCs than low-
medication patients.
Our findings suggest that MDR1 profile of PBMNCs is
associated with seizure severity and medication conditions in
underlying refractory epilepsy patients. The mechanism of these
differences remains elucidated. There have been no animal
experiments for investigating peripheral MDR1 status in epilepsy.
We speculate that prolonged exposure of multiple AEDs could
influence individual variations of MDR1 level, since several of
these drugs are believed to be substrate or inducer of MDR1
[26,27]. We classified drugs as well-known MDR1 substrate
(phenobarbital, oxcarbazepine and lamotrigine) and non-substrate
and analyzed the data. But we couldn’t obtain meaningful
differences among drugs in epilepsy patients. Since there are
many other variables such as duration of administration of each
drug, and controversies about AEDs as MDR1 substrates, further
research is needed to confirm this concept. It is also possible that
the epilepsy influences profile of population of peripheral blood
cells. A severe degree of seizures impair brain cells and this
condition can influence some kind of circulating stem cells [18,28],
and alternately, a subset of PBMNCs, i.e., endothelial progenitor
cells might involve endothelial cell turnover in the brain of epilepsy
patients.
The present findings seem to be consistent with other
researches, which indicate MDR1 status is related to refractoriness
in epilepsy patient. Ideally, we should investigate the MDR1 status
of epilepsy patients in vivo, for example, by using positron
emission tomography with radiolabeled AEDs [29,30]. However,
this is costly and time consuming, whereas the MDR1 status of
PBMNCs is easily analyzed in one day in the laboratory. Although
our study is hampered by study population heterogeneity and low
sample size, our approach is the first attempt to seek a potential
blood marker associated with a variety of epilepsy phenotypes. We
provide novel evidence that the MDR status in PBMNCs can
reflect epilepsy phenotype, and it is potentially altered by
refractory itself or long term AED medication. A prospective
longitudinal study is needed to confirm the predictive value of
MDR1 level.
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Table 4. Multiple logistic regression analysis of factors for the seizure frequency and medication number.
Seizure frequency Medication number
Factors Odd ratio (95% CI) p Value Factors Odd ratio (95% CI) p Value
Temporal lobectomy 12.093 (2.197–66.55) 0.004 Epilepsy duration 1.06 (1–1.116) 0.017
Medication number 2.751 (1.161–6.521) 0.022 Onset age 0.99 (0.99–1) 0.838
Basal MDR1 level 1.16 (1.060–1.268) 0.001 MDR1 conformational change 1.11 (1.02–1.2) 0.008
CI=Confidence interval.
doi:10.1371/journal.pone.0036985.t004
Table 5. Correlation between medication number and
clinical parameters.
Medication number
Parameters Low (n=54) High (n=63) p Value
Number of AEDs 1.660.4 3.960.9 ,0.001
Age (year) 37.4611.6 38.2610.2 0.174
Age of onset (year) 23.3613.1 17.6613.2 0.020*
Duration of epilepsy (year) 13.5610.1 20.6610.8 ,0.001**
Frequency of seizure
(per week)
1.262.7 2.265.7 0.246
Seizure duration (sec) 146.46200.1 78.96114.5 0.033*
BMI 34.867.7 35.568.5 0.650
Hypertension: n (%) 3 (5.6) 7 (11.1) 0.337
Diabetes: n (%) 1 (1.9) 2 (3.2) 1
Hyperlipidemia: n (%) 0 (0) 1 (1.6) 1
Smoking: n (%) 6 (11.1) 8 (12.7) 0.792
Temporal lobectomy: n (%) 4 (7.4) 6 (9.5) 0.751
Febrile seizure: n (%) 7 (13) 12 (19) 0.374
Family history: n (%) 4 (7.4) 4 (6.3) 1
Semiology: (GTCS:
CPS: SPS,%)
58.5:22.6:18.9 55.9:27.1:16.9 0.855
Basal MDR1 level (%) 8.565.1 8.065.2 0.634
Conformational
change level (%)
13.364.6 15.766.3 0.028*
*p,0.05,
**p,0.01.
doi:10.1371/journal.pone.0036985.t005
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